Abbott Partners with Novo Nordisk to Launch Extensior, Expanding Diabetes Care in India

• Abbott and Novo Nordisk India announced a partnership to launch Extensior, a second brand of semaglutide, to expand access to GLP-1 therapy in India.
• Abbott will commercialize Extensior, while Novo Nordisk will supply the semaglutide molecule, globally known as Ozempic.
• Semaglutide is approved for Type 2 diabetes, lowering HbA1c, supporting weight loss, and reducing cardiovascular and kidney risks, with over 49 million patient-years of global use.
• Extensior will be available in FlexTouch pen device in 0.25 mg, 0.5 mg, and 1 mg dose strengths; its price is expected to be lower than Ozempic's current monthly cost of Rs 10,000–Rs 12,000.
• India faces a surging diabetes prevalence, projected to reach 150 million by 2050, with 101 million currently living with diabetes and 136 million pre-diabetic, highlighting the critical need for expanded treatment options.